课题基金 / 基金详情

A novel product for tendinopathy treatment

A novel product for tendinopathy treatment
一种治疗肌腱病的新产品
批准号:
10306057
负责人:
David T Fung
金额:
$2.03万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-15 至 2022-05-31

项目摘要

项目成果

David T Fung的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Tendinopathy is a tendon disorder characterized by tendon deterioration that often leads to tendon rupture, and is associated with pain, swelling and impaired performance. There is currently no cure for tendinopathy. Therefore, there is an urgent need for effective treatments for tendinopathy. The parent award is focused on testing the TenoGen, the product to be developed, exerts a therapeutic effect in mitigating tendinopathy pathology and relieving tendinopathy-related pain and symptoms with no or minimal adverse effects. The purpose of this supplement project is to provide support for an underrepresented researcher to participate and contribute to the R&D of TenoGen within the scope of the parent study. The supplement study will focus on establishing the transcriptome profile of TenoGen treatment using state-of-the-art transcriptomic RNA sequencing (RNA-seq) and bioinformatics technologies. Successful completion of the proposed supplement project is expected to not only provide additional data to accelerate for the R&D and commercialization of TenoGen, but also provide valuable support and an unique opportunity for the candidate’s career development. 1
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
miRNA drug for tendinopathy
miRNA drug for tendinopathy
A novel product for tendinopathy treatment
海外基金